The FDA will review a supplemental NDA from Pfizer (PFE) and Bristol-Myers Squibb (BMY) to...

|About: Pfizer Inc. (PFE)|By:, SA News Editor

The FDA will review a supplemental NDA from Pfizer (PFE) and Bristol-Myers Squibb (BMY) to expand the use of their Eliquis blood thinner to help prevent deep vein thrombosis, which may lead to pulmonary embolism, in adult patients who have undergone hip or knee replacement surgery. The review follows a successful trial for this purpose. The FDA's deadline to decide is March 15, 2014. (PR)